Photo Gallery

Login

Search

News & Updation

  • Updated Version
  • WJPPS introducing updated version of OSTS (online submission and tracking system), which have dedicated control panel for both author and reviewer. Using this control panel author can submit manuscript
  • Call for Paper
    • WJPPS  Invited to submit your valuable manuscripts for Coming Issue.
  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.
  •  
  • WJPPS Impact Factor
  • Its our Pleasure to Inform you that WJPPS Impact Factor has been increased from  7.454 to 7.632  due to high quality Publication at International Level

  • ICV
  • WJPPS Rank with Index Copernicus Value 84.65 due to high reputation at International Level

  • WJPPS: JULY ISSUE PUBLISHED
  • JULY 2021 Issue has been successfully launched on 1 July 2021.

Abstract

A STUDY ON THE SAFETY PROFILE AND CLINICAL OUTCOMES IN PATIENTS USING TULOBUTEROL TRANSDERMAL PATCH AS AN ADD ON THERAPY IN STABLE CHRONIC OBSTRUCTIVE PULMONARY DISEASE

Mekha Monsi Chenthiyethu*, Jerin James, Ruben Thomas Lal, Prof. Dr. Christy K. Jose and Prof. Dr. Santhosh M. Mathews

ABSTRACT

Chronic Obstructive Pulmonary Disease (COPD) is a leading cause of morbidity and mortality and is increasing in prevalence. COPD causes progressive airflow limitation which is not fully reversible associated with abnormal inflammatory response of lungs on exposure to noxious particles or gases. This leads to decline in lung function, exacerbation risk affecting the daily activities of a person and mental health. Although there are medications in preventing the exacerbation risk in COPD, patients still express dissatisfaction for better QOL. Our study assessed the safety profile and clinical outcomes in patients using Tulobuterol transdermal patch as an add on therapy in stable chronic obstructive pulmonary disease. A longitudinal observational study was conducted in 70 patients who were diagnosed with COPD who were selected based on the inclusion and exclusion criteria. The patients were then monitored for improvement in symptoms using CAT, CCQ and mMRC dyspnea scale. Incidence of adverse events were evaluated and patients quality of life using EQ-5D-3L scale. In the study population, COPD occurred with increasing age above 40 and smokers had high prevalence of developing COPD compared to non-smokers and male population had higher prevalence for COPD. Patients showed significant improvement in their symptoms and quality of life and among 70 patients enrolled in the study only 2 patients showed the incidence if adverse events using the Tulobuterol transdermal patch. Our findings are compatible suggesting that Tulobuterol transdermal patch can be given in COPD patients along with inhalers showing significant improvement in patient’s quality of life and symptoms.

Keywords: COPD; TULOBUTEROL; QOL; PREVALENCE; EXACERBATION.


[Full Text Article]

Call for Paper

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More

Online Submission

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More

Email & SMS Alert

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More